Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men

• Published in: Urology (Ridgewood, N.J.) Vol. 61; no. 5; pp. 987 - 992
• Main Authors: Gueye, S.M, Zeigler-Johnson, C.M, Friebel, T, Spangler, E, Jalloh, M, MacBride, S, Malkowicz, S.B, Rebbeck, T.R
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-05-2003; Elsevier Science
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Black or African American; Black People; Case-Control Studies; Humans; Male; Medical sciences; Middle Aged; Neoplasm Staging - statistics & numerical data; Nephrology. Urinary tract diseases; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - epidemiology; Prostatic Neoplasms - ethnology; Senegal - epidemiology; Senegal - ethnology; Tropical medicine; Tumors of the urinary system; Urinary tract. Prostate gland; White People; United States; Senegal; North America; Africa; America; Human; Ethnic origin; Urinary system disease; Prostate disease; American; Exploration; Malignant tumor; African; Prostate specific antigen; Symptomatology; Race; Adult; Diagnosis; Caucasoid; Male genital diseases; Prostate; Comparative study; African American
• ISSN: 0090-4295; 1527-9995; 1527-9995
• DOI: 10.1016/S0090-4295(02)02588-8

To describe the clinical features of prostate cancer in Senegalese men and compare these features with those found in African-American and white American men.
We identified an unselected series of 121 patients with prostate cancer diagnosed at two hospitals in Dakar, Senegal between 1997 and 2002. Medical record abstractions were undertaken to evaluate the prostate tumor characteristics, patient age at diagnosis, prostate-specific antigen (PSA) levels, and reason for referral. In addition, these characteristics were compared with a sample of 455 U.S. white men and 60 African-American men with prostate cancer who were studied as part of a prostate cancer case-control study.
Senegalese men had a significantly worse tumor stage than Americans (41.3% versus 18.8%,
P <0.001), a significantly worse mean PSA level at diagnosis (mean PSA 72.7 ng/mL versus 9.0 ng/mL in Americans;
P <0.001), and were diagnosed at a significantly later age than U.S. men (69 years versus 61 years,
P <0.001). U.S. men were most likely to be diagnosed with prostate cancer after an elevated PSA test, and Senegalese men were most often diagnosed after presenting for prostate-related symptoms.
These observations are not unexpected given the differences in the patterns of prostate cancer screening and health care in the United States compared with Senegal. However, our data provide descriptive information about the characteristics of prostate cancer diagnosed in Senegal and highlight differences in the characteristics and detection of these tumors across populations with very different healthcare systems.